Literature DB >> 11120939

Pharmacodynamics of telithromycin In vitro against respiratory tract pathogens.

I Odenholt1, E Löwdin, O Cars.   

Abstract

Telithromycin (HMR 3647) is a new ketolide that belongs to a new class of semisynthetic 14-membered-ring macrolides which have expanded activity against multidrug-resistant gram-positive bacteria. The aim of the present study was to investigate different basic pharmacodynamic properties of this new compound. The following studies of telithromycin were performed: (i) studies of the rate and extent of killing of respiratory tract pathogens with different susceptibilities to erythromycin and penicillin exposed to a fixed concentration that corresponds to a dose of 800 mg in humans, (ii) studies of the rate and extent of killing of telithromycin at five different concentrations, (iii) studies of the rate and extent of killing of the same pathogens at three different inocula, (iv) studies of the postantibiotic effect and the postantibiotic sub-MIC effect of telithromycin, and (v) determination of the rate and extent of killing of telithromycin in an in vitro kinetic model. In conclusion, telithromycin exerted an extremely fast killing of all strains of Streptococcus pneumoniae both with static concentrations and in the in vitro kinetic model. A slower killing of the strains of Streptococcus pyogenes was noted, with regrowth in the kinetic model of a macrolide-lincosamide-streptogramin B-inducible strain. The strains of Haemophilus influenzae were not killed at all at a concentration of 0.6 mg/liter due to high MICs. A time-dependent killing was seen for all strains. No inoculum effect was seen for the strains of S. pneumoniae, with a 99.9% reduction in the numbers of CFU for all inocula at both 8 h and 24 h. The killing of the strains of S. pyogenes was reduced by 1 log(10) CFU at 8 h and 2 to 3 log(10) CFU at 24 h when the two lower inocula were used but not at all at 8 and 24 h when the highest inoculum was used. For both of the H. influenzae strains there was an inoculum effect, with 1 to 2 log(10) CFU less killing for the inoculum of 10(8) CFU/ml in comparison to that for the inoculum of 10(6) CFU/ml. Overall, telithromycin exhibited long postantibiotic effects and postantibiotic sub-MIC effects for all strains investigated.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11120939      PMCID: PMC90234          DOI: 10.1128/AAC.45.1.23-29.2001

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  16 in total

1.  Comparative in-vitro activity of ketolide HMR 3647 and four macrolides against gram-positive cocci of known erythromycin susceptibility status.

Authors:  J M Hamilton-Miller; S Shah
Journal:  J Antimicrob Chemother       Date:  1998-06       Impact factor: 5.790

2.  Antipneumococcal activities of a ketolide (HMR 3647), a streptogramin (quinupristin-dalfopristin), a macrolide (erythromycin), and a lincosamide (clindamycin).

Authors:  A L Barry; P C Fuchs; S D Brown
Journal:  Antimicrob Agents Chemother       Date:  1998-04       Impact factor: 5.191

3.  Pharmacodynamic effects of sub-MICs of benzylpenicillin against Streptococcus pyogenes in a newly developed in vitro kinetic model.

Authors:  E Löwdin; I Odenholt; S Bengtsson; O Cars
Journal:  Antimicrob Agents Chemother       Date:  1996-11       Impact factor: 5.191

4.  Penetration of ampicillin and dicloxacillin into tissue cage fluid in rabbits: relation to serum and tissue protein binding.

Authors:  O Cars; C Henning; S E Holm
Journal:  Scand J Infect Dis       Date:  1981

Review 5.  Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men.

Authors:  W A Craig
Journal:  Clin Infect Dis       Date:  1998-01       Impact factor: 9.079

6.  Susceptibilities of penicillin- and erythromycin-susceptible and -resistant pneumococci to HMR 3647 (RU 66647), a new ketolide, compared with susceptibilities to 17 other agents.

Authors:  G A Pankuch; M A Visalli; M R Jacobs; P C Appelbaum
Journal:  Antimicrob Agents Chemother       Date:  1998-03       Impact factor: 5.191

7.  Pharmacodynamic properties of HMR 3647, a novel ketolide, on respiratory pathogens, enterococci and Bacteroides fragilis demonstrated by studies of time-kill kinetics and postantibiotic effect.

Authors:  F J Boswell; J M Andrews; R Wise
Journal:  J Antimicrob Chemother       Date:  1998-02       Impact factor: 5.790

8.  In vitro activities of the new ketolide antibiotics HMR 3004 and HMR 3647 against Streptococcus pneumoniae in Germany.

Authors:  R R Reinert; A Bryskier; R Lütticken
Journal:  Antimicrob Agents Chemother       Date:  1998-06       Impact factor: 5.191

9.  Postantibiotic effects and postantibiotic sub-MIC effects of roxithromycin, clarithromycin, and azithromycin on respiratory tract pathogens.

Authors:  I Odenholt-Tornqvist; E Löwdin; O Cars
Journal:  Antimicrob Agents Chemother       Date:  1995-01       Impact factor: 5.191

Review 10.  Pharmacodynamics of macrolides, azalides, and streptogramins: effect on extracellular pathogens.

Authors:  C Carbon
Journal:  Clin Infect Dis       Date:  1998-07       Impact factor: 9.079

View more
  18 in total

1.  Pharmacodynamic functions: a multiparameter approach to the design of antibiotic treatment regimens.

Authors:  Roland R Regoes; Camilla Wiuff; Renata M Zappala; Kim N Garner; Fernando Baquero; Bruce R Levin
Journal:  Antimicrob Agents Chemother       Date:  2004-10       Impact factor: 5.191

2.  CEM-101 activity against Gram-positive organisms.

Authors:  Leah N Woosley; Mariana Castanheira; Ronald N Jones
Journal:  Antimicrob Agents Chemother       Date:  2010-02-22       Impact factor: 5.191

3.  Pharmacodynamic profile of telithromycin against macrolide- and fluoroquinolone-resistant Streptococcus pneumoniae in a neutropenic mouse thigh model.

Authors:  Pamela R Tessier; Holly M Mattoes; Prachi K Dandekar; Charles H Nightingale; David P Nicolau
Journal:  Antimicrob Agents Chemother       Date:  2005-01       Impact factor: 5.191

Review 4.  Ketolides--the modern relatives of macrolides : the pharmacokinetic perspective.

Authors:  Markus Zeitlinger; Claudia Christina Wagner; Birgit Heinisch
Journal:  Clin Pharmacokinet       Date:  2009       Impact factor: 6.447

5.  Ketolide antimicrobial activity persists after disruption of interactions with domain II of 23S rRNA.

Authors:  Guy W Novotny; Lene Jakobsen; Niels M Andersen; Jacob Poehlsgaard; Stephen Douthwaite
Journal:  Antimicrob Agents Chemother       Date:  2004-10       Impact factor: 5.191

Review 6.  Telithromycin.

Authors:  Keri Wellington; Stuart Noble
Journal:  Drugs       Date:  2004       Impact factor: 9.546

Review 7.  The ketolides: a critical review.

Authors:  George G Zhanel; Michael Walters; Ayman Noreddin; Lavern M Vercaigne; Aleksandra Wierzbowski; John M Embil; Alfred S Gin; Stephen Douthwaite; Daryl J Hoban
Journal:  Drugs       Date:  2002       Impact factor: 9.546

8.  [Update to the Latin American Thoracic Association (ALAT) recommendations on community acquired pneumonia].

Authors: 
Journal:  Arch Bronconeumol       Date:  2004-08       Impact factor: 4.872

9.  The Use of Ketolides in Treatment of Upper Respiratory Tract Infections.

Authors:  George G. Zhanel; Aleksandra K. Wierzbowski; PhD Hisanaga; Daryl J. Hoban
Journal:  Curr Infect Dis Rep       Date:  2004-06       Impact factor: 3.725

Review 10.  Dead bugs don't mutate: susceptibility issues in the emergence of bacterial resistance.

Authors:  Charles W Stratton
Journal:  Emerg Infect Dis       Date:  2003-01       Impact factor: 6.883

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.